Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 16Sarcoma 1NET 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Gliosarcoma 131Glioblastoma 128Central Nervous System Neoplasms 58Glioma 51Brain Neoplasms 48Astrocytoma 45Oligodendroglioma 32Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Neuroblastoma 14Medulloblastoma 14Ependymoma 14Osteosarcoma 10Neoplasms 6Choroid Plexus Neoplasms 6Wilms Tumor 5Recurrence 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Glioma, Subependymal 5Familial ependymoma 5Rhabdoid Tumor 4Pinealoma 4Optic Nerve Glioma 4Neuroectodermal Tumors, Primitive 4Leiomyosarcoma 4Diffuse Intrinsic Pontine Glioma 4Testicular Neoplasms 3Kidney Neoplasms 3

Interventions

Gemcitabine 5Docetaxel 4tislelizumab 3Bortezomib 3spartalizumab 2pembrolizumab 2Nivolumab 2Irinotecan 2Filgrastim 2Cisplatin 2Capecitabine 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1tinostamustine 1talazoparib 1surufatinib 1regorafenib 1pazopanib 1pamiparib 1liposomal doxorubicin 1isophosphamide mustard 1futibatinib 1etoposide phosphate 1entinostat 1cc-486 1cabozantinib 1atezolizumab 1anlotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Temozolomide × Sarcoma × Clear all
NCT03150810 2024-12-20

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

BeiGene

Phase 1 Completed
139 enrolled 36 charts
BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡